METASTATIC COLORECTAL CANCER

This study aimed to see if adjusting the dose of a standard chemotherapy drug (5-FU) based on its level in a patient's blood could improve treatment for metastatic colorectal cancer. It planned to test this personalized dosing approach in adults newly diagnosed with advanced colo…

This study is testing whether using anti-EGFR drugs like panitumumab or cetuximab earlier in treatment can better control metastatic colorectal cancer and allow patients to be retreated with these drugs later. It will enroll 71 adults with left-sided, metastatic colon cancer that…

This large, late-stage trial is comparing two immunotherapy approaches against standard chemotherapy for people with advanced colorectal cancer that has spread and has specific genetic features (MSI-H/dMMR). The study aims to see if the immunotherapy drugs nivolumab alone or comb…

This study aimed to test a new combination treatment for advanced colon cancer that has spread and is resistant to standard immunotherapies. It planned to give patients two immunotherapy drugs (tiragolumab and atezolizumab) along with a short, targeted course of radiation. The go…

This study is testing whether adding an experimental drug called onvansertib to standard chemotherapy works better for people with advanced colorectal cancer that has spread and has specific genetic changes (KRAS or NRAS mutations). It involves 113 participants who haven't had pr…

This study is testing if a new type of catheter can better target radiation to liver tumors during a standard treatment called radioembolization. About 20 adults with liver cancer will have their standard treatment planning scan done with either the new device or a standard cathe…

This study is testing whether adding two targeted drugs (encorafenib and cetuximab) to an immunotherapy drug (pembrolizumab) works better than the immunotherapy alone for people with a specific type of advanced colorectal cancer that has spread. It is for adults whose cancer has …

This study is testing two experimental drugs, AK112 and AK117, either alone or together, for people with metastatic colorectal cancer that has spread and cannot be surgically removed. The main goals are to see if these drugs can shrink tumors, control the cancer's growth, and are…

This large Phase 3 trial is comparing two different drug combinations as first treatment for advanced colorectal cancer that has spread and has specific genetic markers (RAS/BRAF wild-type). 748 participants will receive either the experimental combination (anlotinib plus chemoth…

This study aimed to test whether a two-part experimental immunotherapy could help control advanced colorectal cancer that had stopped responding to all standard treatments. It was designed for patients whose cancer had spread and who had already tried and failed at least three pr…

This study tests whether adding hydroxychloroquine (an anti-malaria drug) to standard chemotherapy helps control metastatic colorectal cancer in patients whose tumors show signs of drug resistance. About 155 patients will be screened, with up to 31 receiving the full four-drug co…

This study compares two different drug combinations for people with metastatic colorectal cancer who cannot receive intensive chemotherapy. Researchers want to see if one combination works better than the other at controlling cancer growth and extending life. The trial involves 8…

This study is testing whether new immunotherapy drugs called botensilimab and balstilimab can help control advanced colon cancer that has spread and stopped responding to standard chemotherapy. The trial will compare these drugs given alone or together against current standard tr…

This study aims to learn if tracking cancer DNA in the blood can predict how well standard chemotherapy works for people with advanced colorectal cancer that has stopped responding to prior treatments. It observes 103 patients receiving their doctor's chosen standard therapy, col…